Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.30 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4189177 | 0.86 | DPP4 (0.34) | MAPTLMNAHTTS1PR4KDM4E | |
| SCHEMBL4346182 | 0.81 | ALDH1A1 (0.47) | MAPTHTTKDM4EMEN1PKM | |
| SCHEMBL5127613 | 0.81 | ALDH1A1 (0.47) | MAPTHTTKDM4EMEN1PKM | |
| SCHEMBL4336371 | 0.81 | TSHR (0.39) | MAPTLMNAS1PR4KDM4EMEN1 | |
| SCHEMBL27767811 | 0.78 | SLC6A4 (0.31) | SLC6A4S1PR4 | |
| SCHEMBL5117607 | 0.77 | MAPT (0.37) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL4335626 | 0.77 | MAPT (0.37) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL4189589 | 0.77 | MAPT (0.37) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL14267045 | 0.71 | SMN1; SMN2 (0.38) | MAPTLMNAHTTS1PR4PKM | |
| SCHEMBL3204875 | 0.71 | ALDH1A1 (0.50) | MAPTHTTKDM4EMEN1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027105-A2 | NOVEL PROCESS FOR PREPARING INTERMEDIATES OF CCR ANTAGONISTS | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | claimed |
| US-20080064884-A1 | Novel Process 1 | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | claimed |
| WO-2007129960-A2 | NOVEL PROCESSES FOR PREPARING INTERMEDIATES OF CCR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| EP-2027105-A2 | NOVEL PROCESS FOR PREPARING INTERMEDIATES OF CCR ANTAGONISTS | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | disclosed |
| US-20080064884-A1 | Novel Process 1 | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064884-A1 | Novel Process 1 | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064884-A1 | Novel Process 1 | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| WO-2007129960-A2 | NOVEL PROCESSES FOR PREPARING INTERMEDIATES OF CCR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007129960-A2 | NOVEL PROCESSES FOR PREPARING INTERMEDIATES OF CCR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064884-A1 | Novel Process 1 | TPX2, UGT1A1, BRIX1 | MAPT 4422/4885LMNA 2842/4885HTT 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.